Dyadic completes dosing in Phase 1 COVID-19 vaccine trial; no SAEs, Q2 data update expected

DYADIC INTERNATIONAL INC

DYAI-100 COVID-19 booster vaccine trial: dosing of low and high dose groups completed Feb 2023.
No serious adverse events reported; vaccine well tolerated to date.
Initial safety and antibody response update expected in Q2 2023.
First human test of C1-cell platform for vaccines; CEO notes increased interest from academia/industry.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.